Recombinant expression and downstream processing of the disulfide‑rich tumor‑targeting peptide chlorotoxin

Wang,Xiao‑Min; Luo,Xiao; Guo,Zhan‑Yun

doi:10.3892/etm.2013.1234

Recombinant expression and downstream processing of the disulfide‑rich tumor‑targeting peptide chlorotoxin

Authors:
- Xiao‑Min Wang
- Xiao Luo
- Zhan‑Yun Guo
View Affiliations

Affiliations: Institute of Protein Research, College of Life Sciences and Technology, Tongji University, Shanghai 200092, P.R. China
Published online on: July 24, 2013 https://doi.org/10.3892/etm.2013.1234
Pages: 1049-1053

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chlorotoxin (CTX) is a scorpion‑derived disulfide‑rich peptide that targets malignant tumors by binding the cell surface matrix metalloproteinase‑2 and annexin A2. Various CTXs labeled with functional moieties have shown great potential for tumor diagnosis and treatment. In the present study, we established an efficient approach for preparing mature CTX that may be used for experimental and therapeutic purposes. The designed CTX precursors carried either a 6xHis‑tag or a 6xHis‑tag and a glutathione transferase (GST)‑tag and were recombinantly expressed in Escherichia coli. Following S‑sulfonation, the precursors were purified using immobilized metal‑ion affinity chromatography. Subsequent to the removal of the tag by enterokinase cleavage and in vitro oxidative refolding, mature CTX was obtained with a considerable yield. The yield of mature CTX whose precursors carried a 6xHis‑tag and a GST‑tag (2 mg per liter of culture) was ~10‑fold that of the mature CTX whose precursors carried a 6xHis‑tag (150‑200 µg per liter of culture). The folded CTX inhibited the migration of glioma cells in a concentration‑dependent manner, suggesting it was biologically active.

View Figures

View References

1.	DeBin JA, Maggio JE and Strichartz GR: Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am J Physiol. 264:C361–C369. 1993.PubMed/NCBI
2.	Soroceanu L, Gillespie Y, Khazaeli MB and Sontheimer H: Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. 58:4871–4879. 1998.PubMed/NCBI
3.	Lyons SA, O’Neal J and Sontheimer H: Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia. 39:162–173. 2002. View Article : Google Scholar : PubMed/NCBI
4.	Deshane J, Garner CC and Sontheimer H: Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem. 278:4135–4144. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Kesavan K, Ratliff J, Johnson EW, et al: Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem. 285:4366–4374. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Huang R, Han L, Li J, et al: Chlorotoxin-modified macromolecular contrast agent for MRI tumor diagnosis. Biomaterials. 32:5177–5186. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Kievit FM, Veiseh O, Fang C, Bhattarai N, Lee D, Ellenbogen RG and Zhang M: Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano. 4:4587–4594. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Orndorff RL and Rosenthal SJ: Neurotoxin quantum dot conjugates detect endogenous targets expressed in live cancer cells. Nano Lett. 9:2589–2599. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Sun C, Veiseh O, Gunn J, et al: In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small. 4:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Sun C, Fang C, Stephen Z, et al: Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine (Lond). 3:495–505. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Veiseh M, Gabikian P, Bahrami SB, et al: Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 67:6882–6888. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Veiseh O, Kievit FM, Gunn JW, Ratner BD and Zhang M: A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials. 30:649–657. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Veiseh O, Gunn JW, Kievit FM, Sun C, Fang C, Lee JS and Zhang M: Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small. 5:256–264. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Veiseh O, Sun C, Fang C, et al: Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 69:6200–6207. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Jacoby DB, Dyskin E, Yalcin M, et al: Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide. Anticancer Res. 30:39–46. 2010.PubMed/NCBI
16.	The MICAD Research Team: 131I-Chlorotoxin. Molecular Imaging and Contrast Agent Database (MICAD). National Center for Biotechnology Information (US); 2004–2013